FDA Rejects Ardelyx Chronic Kidney Disease Drug

The FDA has denied Ardelyx’s new drug application (NDA) for tenapanor as a treatment for chronic kidney disease in adults on dialysis, citing concerns over the treatment’s effectiveness.
Source: Drug Industry Daily